Mitsubishi UFJ Asset Management Co. Ltd. Purchases 11,910 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Mitsubishi UFJ Asset Management Co. Ltd. increased its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 3.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 411,736 shares of the medical equipment provider’s stock after purchasing an additional 11,910 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. owned about 0.21% of Zimmer Biomet worth $37,064,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Rakuten Investment Management Inc. acquired a new stake in Zimmer Biomet in the 3rd quarter valued at $37,307,000. Sector Gamma AS boosted its stake in Zimmer Biomet by 28.0% in the third quarter. Sector Gamma AS now owns 113,478 shares of the medical equipment provider’s stock worth $11,178,000 after purchasing an additional 24,847 shares in the last quarter. SG Americas Securities LLC boosted its stake in Zimmer Biomet by 29.2% in the third quarter. SG Americas Securities LLC now owns 61,110 shares of the medical equipment provider’s stock worth $6,019,000 after purchasing an additional 13,812 shares in the last quarter. Border to Coast Pensions Partnership Ltd boosted its stake in Zimmer Biomet by 6.5% in the third quarter. Border to Coast Pensions Partnership Ltd now owns 360,462 shares of the medical equipment provider’s stock worth $35,506,000 after purchasing an additional 22,104 shares in the last quarter. Finally, National Pension Service boosted its stake in Zimmer Biomet by 4.5% in the third quarter. National Pension Service now owns 393,476 shares of the medical equipment provider’s stock worth $38,757,000 after purchasing an additional 16,928 shares in the last quarter. 88.89% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, SVP Lori Winkler sold 2,650 shares of the company’s stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $94.66, for a total value of $250,849.00. Following the completion of the sale, the senior vice president owned 10,224 shares in the company, valued at approximately $967,803.84. This represents a 20.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 1.28% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Citizens Jmp cut their price target on Zimmer Biomet from $120.00 to $105.00 and set a “market outperform” rating on the stock in a research note on Wednesday, April 29th. Leerink Partners assumed coverage on Zimmer Biomet in a research note on Monday, April 13th. They set a “hold” rating and a $101.00 price target on the stock. Weiss Ratings raised Zimmer Biomet from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, April 7th. JPMorgan Chase & Co. cut their price target on Zimmer Biomet from $100.00 to $95.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 29th. Finally, Truist Financial reaffirmed a “hold” rating and set a $92.00 price target (down from $98.00) on shares of Zimmer Biomet in a research note on Wednesday, April 29th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have given a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $102.80.

Zimmer Biomet Trading Down 1.4%

NYSE ZBH opened at $82.24 on Friday. The stock has a 50-day simple moving average of $91.56 and a 200 day simple moving average of $92.31. The company has a market capitalization of $15.91 billion, a PE ratio of 21.36, a P/E/G ratio of 1.90 and a beta of 0.48. The company has a current ratio of 1.73, a quick ratio of 0.95 and a debt-to-equity ratio of 0.50. Zimmer Biomet Holdings, Inc. has a 12 month low of $79.83 and a 12 month high of $108.29.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Tuesday, April 28th. The medical equipment provider reported $2.09 EPS for the quarter, beating analysts’ consensus estimates of $1.86 by $0.23. The business had revenue of $2.09 billion during the quarter, compared to the consensus estimate of $2.07 billion. Zimmer Biomet had a return on equity of 13.24% and a net margin of 9.05%.The firm’s revenue was up 9.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.81 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. Research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.47 EPS for the current year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, April 30th. Investors of record on Tuesday, March 31st were issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 1.2%. The ex-dividend date was Tuesday, March 31st. Zimmer Biomet’s dividend payout ratio is currently 24.94%.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.